MedTrace Logo

Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)

NCT02933021 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 664

Last updated 2020-09-02

No results posted yet for this study

Summary

This is a study to investigate the functional consequences of paraprotein production in MGUS (Monoclonal Gammopathy of Unknown Significance).

Conditions

  • Monoclonal Gammopathy of Unknown Significance

Interventions

OTHER

Blood sample taken

OTHER

Answering a lifestyle questionnaire

OTHER

Follow-up phone call from researcher (two years after first visit)

To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.

Sponsors & Collaborators

  • RxCelerate Limited

    collaborator UNKNOWN

  • RxCelerate Ltd

    lead INDUSTRY

Principal Investigators

  • Jill Reckless · RxCelerate Limited

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-02-28
Completion
2021-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933021 on ClinicalTrials.gov